Yapin Niu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Yapin Niu has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Feng Sun
Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing, China
1 shared publication - Fengqi Liu
Department of Epidemiology and Biostatistics Peking University School of Public Health, Beijing 100083, China
1 shared publication - Sanbao Chai
Department of Endocrinology and Metabolism, Peking University International Hospital, Beijing 102206, China
1 shared publication - Shanshan Wu
Department of Gastroenterology Beijing Friendship Hospital, Capital Medical University Beijing China
1 shared publication - Zhi-Rong Yang
Department of Computational Biology and Medical Big Data, Faculty of Computer Science and Artificial Intelligence, Shenzhen University of Advanced Technology, Shenzhen 518107, China
1 shared publication
Latest Publications
- Open Access
- 1 January 2024
- Published by Wiley in Journal of Diabetes Research
- Vol. 2024 (1) , 8145388
Comparison of GLP‐1 Receptor Agonists, SGLT‐2 Inhibitors, and DPP‐4 Inhibitors as an Add‐On Drug to Insulin Combined With Oral Hypoglycemic Drugs: Umbrella Review
Background: The objective was to evaluate the efficacy of the combination of Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs), dipeptidyl peptidase‐4 inhibitors (DPP‐4i), and sodium‐glucose cotransporter 2 inhibitor (SGLT‐2i) in the treatment of Type 2 diabetes with poor efficacy of basic insulin and metformin/sulfonylurea by umbrella review.Materials and Methods: Forming the data of publication of each database through 13 September 2022, PubMed, EMBASE, and Cochrane Library were surveyed.Results: A total of seven meta‐analyses were included in the umbrella review. The combination of GLP‐1 RA (WMD −3.41 [−5.61, −1.21], p = 0.002), SGLT‐2i (WMD −5.34 [−9.56, −1.13], p = 0.013), and DPP‐4i (WMD −5.56 [−7.39, −3.73], p ≤ 0.001) can significantly reduce HbA1c levels, respectively. The combination of GLP‐1 RA (WMD −1.55 [−2.92, −0.18], p = 0.027), SGLT‐2i (WMD −2.96 [−6.68, 0.77], p = 0.12), and DPP‐4i (WMD −2.05 [−2.82, −1.28], p ≤ 0.001) can significantly reduce fasting plasma glucose (FPG) levels, respectively. The combination of GLP‐1 RA (WMD −3.24 [−5.14, −1.34], p < 0.001) can significantly reduce body weight of Type 2 diabetes mellitus (T2DM). The dose of basic insulin in diabetes patients after combined use of GLP‐1 RA (WMD −2.74 [−4.26, −1.22], p ≤ 0.001) was significantly reduced. The combination use of GLP‐1 RAs (OR 1.28 [1.05, 1.56], p = 0.017) increases the risk of hypoglycemia.Conclusions: The combination of GLP‐1 RAs, DPP‐4i, and SGLT‐2i can effectively lower HbA1c and FPG in T2DM patients who have poor therapeutic effects on basic insulin combined with metformin/sulfonylureas, respectively. Compared to placebo, GLP‐1 RAs can significantly reduce body weight and basic insulin dosage, while DPP‐4i and SGLT‐2i have a lower risk of hypoglycemia.Trial Registration:CRD42023410345.
- 1 January 2024
- Published by Wiley in Journal of Diabetes Research
- Vol. 2024 (1) , 8145388
Open AccessComparison of GLP‐1 Receptor Agonists, SGLT‐2 Inhibitors, and DPP‐4 Inhibitors as an Add‐On Drug to Insulin Combined With Oral Hypoglycemic Drugs: Umbrella Review
Background: The objective was to evaluate the efficacy of the combination of Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs), dipeptidyl peptidase‐4 inhibitors (DPP‐4i), and sodium‐glucose cotransporter 2 inhibitor (SGLT‐2i) in the treatment of Type 2 diabetes with poor efficacy of basic insulin and metformin/sulfonylurea by umbrella review.Materials and Methods: Forming the data of publication of each database through 13 September 2022, PubMed, EMBASE, and Cochrane Library were surveyed.Results: A total of seven meta‐analyses were included in the umbrella review. The combination of GLP‐1 RA (WMD −3.41 [−5.61, −1.21], p = 0.002), SGLT‐2i (WMD −5.34 [−9.56, −1.13], p = 0.013), and DPP‐4i (WMD −5.56 [−7.39, −3.73], p ≤ 0.001) can significantly reduce HbA1c levels, respectively. The combination of GLP‐1 RA (WMD −1.55 [−2.92, −0.18], p = 0.027), SGLT‐2i (WMD −2.96 [−6.68, 0.77], p = 0.12), and DPP‐4i (WMD −2.05 [−2.82, −1.28], p ≤ 0.001) can significantly reduce fasting plasma glucose (FPG) levels, respectively. The combination of GLP‐1 RA (WMD −3.24 [−5.14, −1.34], p < 0.001) can significantly reduce body weight of Type 2 diabetes mellitus (T2DM). The dose of basic insulin in diabetes patients after combined use of GLP‐1 RA (WMD −2.74 [−4.26, −1.22], p ≤ 0.001) was significantly reduced. The combination use of GLP‐1 RAs (OR 1.28 [1.05, 1.56], p = 0.017) increases the risk of hypoglycemia.Conclusions: The combination of GLP‐1 RAs, DPP‐4i, and SGLT‐2i can effectively lower HbA1c and FPG in T2DM patients who have poor therapeutic effects on basic insulin combined with metformin/sulfonylureas, respectively. Compared to placebo, GLP‐1 RAs can significantly reduce body weight and basic insulin dosage, while DPP‐4i and SGLT‐2i have a lower risk of hypoglycemia.Trial Registration:CRD42023410345.